Press releases
2023
1 December, 2023
Save the Date: Egetis to host Investor Day on December 19, 2023
10 November, 2023
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan
8 November, 2023
Interim report Q3 2023
1 November, 2023
Egetis’ Nomination Committee for the 2024 Annual General Meeting
31 October, 2023
Change in the number of shares and votes in Egetis Therapeutics
27 October, 2023
Egetis announces EMA validation of Marketing Authorisation Application for Emcitate for the treatment of MCT8 deficiency
11 October, 2023
Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm
9 October, 2023
Egetis submits marketing authorisation application for Emcitate for treatment of MCT8 deficiency to the European Medicines Agency
25 September, 2023
ReTRIACt trial design presented at the Annual Meeting of the European Society for Paediatric Endocrinology
12 September, 2023
Egetis to participate at medical conferences to increase disease awareness about MCT8 deficiency
30 August, 2023
Egetis to participate at upcoming investor conferences
22 August, 2023
Interim report Q2 2023
24 July, 2023
Egetis announces first patient included and second site activated in the pivotal ReTRIACt trial
28 June, 2023
Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission
16 June, 2023
Board directors in Egetis Therapeutics acquire shares
26 April, 2023
Interim report January-March 2023
30 March, 2023
Egetis comments on market rumors
28 March, 2023
Egetis Therapeutics’ 2022 annual report published